Dr. Rini on the Results From His Axitinib and Sorafenib Trial

Video

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the results of the AXIS 1032 phase III trial comparing axitinib to sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Related Content
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Michael B. Atkins, MD, deputy director, Georgetown Lombardi Comprehensive Cancer Center

Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC

May 11th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Sean McCarthy, DPhil

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024
Article
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024
Article